Infinity Pharmaceuticals stock analysis
Infinity Pharmaceuticals (INFIQ) Stock Price & Analysis
INFIQ Stock Chart & Stats
- Day’s Range
- $0.01 - $0.02
- 52-Week Range
- N/A
- Previous Close
- $0.02
- Volume
- N/A
- Average Volume (3M)
- 2.27M
- Market Cap
- $91
- Enterprise Value
- $49.63M
- Total Cash (Recent Filing)
- $17.75M
- Total Debt (Recent Filing)
- $633.00K
- Price to Earnings (P/E)
- 0.0
- Beta
- -110.71
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
INFIQ FAQ
What is Infinity Pharmaceuticals’s market cap?
When is Infinity Pharmaceuticals’s upcoming earnings report date?
How were Infinity Pharmaceuticals’s earnings last quarter?
Is Infinity Pharmaceuticals overvalued?
Does Infinity Pharmaceuticals pay dividends?
What is Infinity Pharmaceuticals’s EPS estimate?
How many shares outstanding does Infinity Pharmaceuticals have?
What happened to Infinity Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Infinity Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vishal Mehta
- Employees
- 30
- Website
- www.infi.com
- Address
- 1100 Massachusetts Avenue, Cambridge, MA, 02138, US

